Richard Kim MD
Dr. Kim is a seasoned pharmaceutical executive with over 24 years of experience in clinical development and medical affairs, encompassing Phases I through IV, as well as IND and NDA filings. His career spans start-ups, mid-sized biotechs, and large pharmaceutical companies, with proven success across a diverse range of therapeutic areas—from rare orphan diseases to common indications. These include multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, inflammatory neuromuscular disorders (CIDP, cALD and TK2d), endocrinopathies, carcinoid syndrome, cognitive impairment, psoriasis, restless legs syndrome, alcohol use disorder, and post-herpetic neuralgia.
He has direct hands-on involvement with five approved and marketed products: TYSABRI (natalizumab), Horizant (gabapentin enacarbil), Cladribine (Mavenclad), Rebif (interferon beta-1a), and Butrans (buprenorphine transdermal patch). His prior roles include positions at prominent companies such as, EMD Serono, Inc. (medical director for the cladribine Phase 3 program), Biogen Inc. (global medical affairs director for natalizumab/TYSABRI, contributing to its U.S. re-launch and global launch), Elan Pharmaceuticals, Inc. (vice president of clinical development and head of the multiple sclerosis therapeutic area; joint program team leader for TYSABRI), XenoPort, Inc. (vice president of medical affairs supporting Horizant launch, later promoted to senior vice president, clinical development, and medical affairs, and CMO).
Dr. Kim is well-regarded among key opinion leaders (KOLs) in these fields and has progressed through leadership roles focused on personnel mentorship, global program leadership, and serving as a Section 16 chief medical officer. An effective cross-functional leader, he aligns teams across commercial, investor relations, program management, pharmacovigilance, regulatory, business development, and external partnership functions. His blend of scientific expertise, strategic insight, and operational acumen drives the advancement of clinical programs and innovative therapies.